Wang, Linqin
Lv, Yuqi
Zhou, Linghui
Wu, Shenghao
Zhu, Yuanyuan
Fu, Shan
Ding, Shuyi
Hong, Ruimin
Zhang, Mingming
Yu, Hanjing
Chang, Alex H.
Wei, Guoqing
Hu, Yongxian
Huang, He
Funding for this research was provided by:
Discipline Construction Project Fund for Nursing Research, FAHZU (2022ZYHL007)
Medical Science and Technology Project of Zhejiang Provincial Health Commission (2023KY709)
National natural Science Foundation of China (82270235, 82270234)
Sanming Project of Medicine in Shenzhen (SZSM202111004)
Article History
Received: 6 November 2023
Accepted: 26 February 2024
First Online: 5 March 2024
Declarations
:
: Ethics Committee approval was obtained from the First Affiliated Hospital, School of Medicine, Zhejiang University Institutional Review Board to the commencement of the study.
: AHC is a founding member of Shanghai YaKe Biotechnology Ltd., a biotechnology company focusing on research and development of tumor cellular immunotherapy. The remaining authors declare no conflict of interest.